What question did this study set out to answer?

This research aims to determine the genetic landscape of dilated cardiomyopathy (DCM) and evaluate next-generation sequencing as a diagnostic tool for its clinical utility.

April 22, 2026Open Access

Genetics and genotype–phenotype correlations in Finnish patients with dilated cardiomyopathy

Key Result

Panel-based next-generation sequencing enables a high diagnostic yield in familial dilated cardiomyopathy and provides reliable clinical genomic interpretation via variant filtering.

Key Points

This research aims to determine the genetic landscape of dilated cardiomyopathy (DCM) and evaluate next-generation sequencing as a diagnostic tool for its clinical utility.
Utilized a targeted sequencing panel with oligonucleotide-selective sequencing (OS-Seq) for 101 genes in 145 unrelated Finnish DCM patients.
Developed bioinformatic variant filtering strategies to enhance diagnostic accuracy and classification.
Measured diagnostic yield by assessing both pathogenic and likely pathogenic variants.
Achieved a diagnostic yield of 35.2%, with familial DCM showing 47.6% and sporadic DCM 25.6% (P = 0.004).
Identified 20 (53%) of the disease-causing variants as titin (TTN) truncations, affecting all TTN transcripts.
TTN truncations represented 20.6% of familial and 14.6% of sporadic DCM cases.

Structured PICO

Does panel-based NGS provide high diagnostic yield in Finnish patients with dilated cardiomyopathy?

Population

Finnish patients with dilated cardiomyopathy (DCM)

Intervention

Panel-based, high-quality Next-Generation Sequencing (NGS) and bioinformatic variant filtering

Outcome

Diagnostic yield

Panel-based NGS provides a high diagnostic yield for familial dilated cardiomyopathy and is reliable for clinical genomic interpretation.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

AIMS: Despite our increased understanding of the genetic basis of dilated cardiomyopathy (DCM), the clinical utility and yield of clinically meaningful findings of comprehensive next-generation sequencing (NGS)-based genetic diagnostics in DCM has been poorly described. We utilized a high-quality oligonucleotide-selective sequencing (OS-Seq)-based targeted sequencing panel to investigate the genetic landscape of DCM in Finnish population and to evaluate the utility of OS-Seq technology as a novel comprehensive diagnostic tool. METHODS AND RESULTS: Using OS-Seq, we targeted and sequenced the coding regions and splice junctions of 101 genes associated with cardiomyopathies in 145 unrelated Finnish patients with DCM. We developed effective bioinformatic variant filtering strategy and implemented strict variant classification scheme to reveal diagnostic yield and genotype-phenotype correlations. Implemented OS-Seq technology provided high coverage of the target region (median coverage 410× and 99.42% of the nucleotides were sequenced at least 15× read depth). Diagnostic yield was 35.2% (familial 47.6% and sporadic 25.6%, P = 0.004) when both pathogenic and likely pathogenic variants are considered as disease causing. Of these, 20 (53%) were titin (TTN) truncations (non-sense and frameshift) affecting all TTN transcripts. TTN truncations accounted for 20.6% and 14.6% of the familial and sporadic DCM cases, respectively. CONCLUSION: Panel-based, high-quality NGS enables high diagnostic yield especially in the familial form of DCM, and bioinformatic variant filtering is a reliable step in the process of interpretation of genomic data in a clinical setting.